_________________
October 4, 2021 | ValGenesis appoints Mike Hicks as Chief Technology Officer. "I am incredibly excited to join a clear market leader and to be part of the innovative leadership team at ValGenesis.
ValGenesis News
ValGenesis appoints Mike Hicks as Chief Technology Officer. "I am incredibly excited to join a clear market leader and to be part of the innovative leadership team at ValGenesis.
ValGenesis, Inc., announced the appointment of Bo Olsen as Head of European Operations. Bo will be in charge of developing business opportunities and expanding ValGenesis's operation in the European region.
ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management Systems (VLMS), today announced the appointment of Kevin Potts as Vice President of Marketing, effective August 1, 2021.
One of the top ten global pharmaceutical companies selected ValGenesis’ eLog solution to meet its global needs for the digitization of logbooks.
ValGenesis, Inc., the market leader in Enterprise Validation Lifecycle Management Systems (VLMS), today announced the appointment of Kevin O’Donnell as Chief Financial Officer, effective August 2, 2021.
A top Italian life sciences company has chosen to implement ValGenesis’ 100% paperless Validation Lifecycle Management System (VLMS) to manage its corporate validation lifecycle process.
Digitization of backend processes and workflow automation is a rapidly emerging area of growth for healthcare and life sciences companies. As a market leader, ValGenesis offers a fit-for-purpose platform for validation lifecycle management, resulting in significant cost and time efficiencies for global, compliance focused organizations.
A U.S. based cell therapies company has selected ValGenesis VLMS – the industry’s most trusted electronic validation lifecycle management system – to digitize multiple corporate validation lifecycle processes across the organization.
An international biosciences company has selected ValGenesis to digitize the validation processes for its products and solutions through a single instance of ValGenesis VLMS with multilingual support that would be accessed by thousands of life science organizations across 40 countries.
A pioneering gene therapy company has selected ValGenesis VLMS for its remote validation capability, and for its ability to enable efficient change and risk management to help the company achieve better control over these processes.